Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamiparib + TC chemotherapy + bevacizumab as neoadjuvant therapy for untreated advanced ovarian cancer (Phase II, single-arm)
ChiCTR2200059119Phase 2Completed
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pamiparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Pathological chemotherapy response score. Started Mar 2023; status: completed.
02
Drugs
pamiparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2200059119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059119.